Who are besivance's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): moxifloxacin / dexamethasone, group-B : Levofloxacin triple therapy, Ciprofloxacin 0.3%, Oral norfloxacin, Renamezin capsule, ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/besivance.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

besivance — Competitive Intelligence Brief

besivance (besivance) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Infectious Disease.

marketed DNA gyrase, Topoisomerase IV Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

besivance (besivance) — Ophthalmology Consultants, Ltd..

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
besivance TARGET	besivance	Ophthalmology Consultants, Ltd.	marketed		DNA gyrase, Topoisomerase IV
moxifloxacin / dexamethasone	moxifloxacin / dexamethasone	Federal University of São Paulo	marketed	Fluoroquinolone antibiotic + corticosteroid combination	Bacterial DNA gyrase, topoisomerase IV, glucocorticoid receptor
group-B : Levofloxacin triple therapy	group-B : Levofloxacin triple therapy	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	marketed	Fluoroquinolone antibiotic combination therapy	Bacterial DNA gyrase, topoisomerase IV
Ciprofloxacin 0.3%	Ciprofloxacin 0.3%	Indiana University School of Medicine	marketed	Fluoroquinolone antibiotic	DNA gyrase, topoisomerase IV
Oral norfloxacin	Oral norfloxacin	Hospital Clinic of Barcelona	marketed	Fluoroquinolone antibiotic	DNA gyrase, topoisomerase IV
Renamezin capsule	Renamezin capsule	Daewon Pharmaceutical Co., Ltd.	marketed	Fluoroquinolone antibiotic	DNA gyrase, Topoisomerase IV
ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin	ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin	University of British Columbia	marketed	Fluoroquinolone, Sulfonamide-diaminopyrimidine combination, Nitrofuran	Bacterial DNA gyrase, topoisomerase IV, dihydrofolate reductase, bacterial DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). besivance — Competitive Intelligence Brief. https://druglandscape.com/ci/besivance. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab